GSK/Vertex Agenerase Prodrug To Target Protease Inhibitor-Naive Patients
Executive Summary
GlaxoSmithKline/Vertex' Agenerase prodrug will target first-time protease inhibitor patients, a market segment that amprenavir has not penetrated, Vertex VP-Corporate Communications Lynne Brum told analysts during a recent conference call.
You may also be interested in...
Vertex/Aurora
Aurora and Vertex merger completes July 18 (1"The Pink Sheet" May 7, p. 18)
Vertex/Aurora
Aurora and Vertex merger completes July 18 (1"The Pink Sheet" May 7, p. 18)
Abbott Kaletra Tops 12% Of PI Market; Synthroid Outlook Is "Very Good"
Abbott expects to claim the number one spot in the protease inhibitor market by the end of 2001 on the strength of the first-year performance of Kaletra (ritonavir/lopinavir).